Finance

Lists
Why is RNTX up 5,98%?
Dive Deeper
RNTX:NASDAQ
Rein Therapeutics Inc
0,85 US$
+5,98%
(+0,048) 1D
0,85 US$
0,00% (0,00)
After hours
Closed: 1 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNTX...
Open
0,80 US$
High
0,90 US$
Low
0,76 US$
Mkt. cap
73,88 მლნ.
Avg. vol.
446,53 ათ.
Volume
1,11 მლნ.
52-wk high
2,18 US$
52-wk low
0,69 US$
EPS
-1,59 US$
Beta
1,37
Shares outstanding
86,27 მლნ.
No. of employees
10
Open
0,80 US$
High
0,90 US$
Low
0,76 US$
Mkt. cap
73,88 მლნ.
Avg. vol.
446,53 ათ.
Volume
1,11 მლნ.
52-wk high
2,18 US$
52-wk low
0,69 US$
EPS
-1,59 US$
Beta
1,37
Shares outstanding
86,27 მლნ.
No. of employees
10
News stories
From web sources and news partners
MarketBeat
MarketBeat
·
21 წუთის წინ
Insider Buying: PodcastOne (NASDAQ:PODC) Director Purchases 7,000 Shares of Company Stock
Nasdaq
Nasdaq
·
36 წუთის წინ
A Quarter of Companies Have No Analyst Coverage
MarketWatch
MarketWatch
·
25 წუთის წინ
Here’s who’s joining the S&P 500 in the index’s latest shakeup
Yahoo Finance
Yahoo Finance
·
2 საათის წინ
Why this analyst sees 15% upside for the S&P 500
About Rein Therapeutics Inc
CEO-
Employees10
Founded2001
Headquartersოსტინი, ტეხასი, ამერიკის შეერთებული შტატები
Sector-
Websitereintx.com
Analyst ratings
Based on 2 analysts giving stock ratings to RNTX in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for RNTX in the last 3 months.
Highest
Current 0,85 US$
8,00 US$ (+838,86%)
Average
6,00 US$ (+604,14%)
Lowest
4,00 US$ (+369,43%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brandon Folkes
H.C. Wainwright
Buy
Maintained
8,00 US$
+838,9%
09/21/2026
Jason McCarthy
Maxim Group
Buy
Maintained
4,00 US$
+369,4%
08/17/2026
Kemp Dolliver
Brookline Capital Markets
Hold
Downgraded
-
-
01/21/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1,68 მლნ.
2,00 მლნ.
3,07 მლნ.
3,64 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,81 მლნ.
1,96 მლნ.
2,16 მლნ.
2,44 მლნ.
Operating expense
5,49 მლნ.
3,96 მლნ.
5,23 მლნ.
6,08 მლნ.
Total operating expenses
5,49 მლნ.
3,96 მლნ.
5,23 მლნ.
6,08 მლნ.
Operating income
-5,49 მლნ.
-3,96 მლნ.
-5,23 მლნ.
-6,08 მლნ.
Other non operating income
-89,00 ათ.
-20,00 ათ.
-608,00 ათ.
-299,00 ათ.
EBT including unusual items
-5,58 მლნ.
-32,68 მლნ.
-5,84 მლნ.
-6,38 მლნ.
EBT excluding unusual items
-5,58 მლნ.
-3,98 მლნ.
-5,84 მლნ.
-6,38 მლნ.
Income tax expense
-
-712,00 ათ.
-
-
Effective tax rate
-
2,18%
-
-
Other operating expenses
-
-
-
-
Net income
-5,58 მლნ.
-31,97 მლნ.
-5,84 მლნ.
-6,38 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-5,49 მლნ.
-3,96 მლნ.
-5,23 მლნ.
-6,08 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები